The biotech and healthcare sectors in the United Kingdom experienced a remarkable year in 2024, marked by substantial financial investments, significant trends, and notable challenges. Grounded in a report by the UK BioIndustry Association (BIA), this analysis delves into the pivotal investment
10x Genomics, under the leadership of co-founder and CEO Serge Saxonov, PhD, is making a strategic shift towards enhancing customer support and expanding its presence in the biopharma market. Following a prolific year of product launches in 2024, the company is now focusing on promoting its recent
Bill Gates' significant role in global health policy, especially through the Bill & Melinda Gates Foundation, raises critical questions about philanthropy's impact on international health and the sustainability of biologics manufacturing. The Foundation is known for its substantial contributions to
The biopharma industry stands at a transformative juncture as it reflects on the achievements of the past year and anticipates the evolving client requirements that will shape 2025 and beyond. Key insights from Subodh Deshmukh, CEO of Aragen Bioscience, highlight the crucial areas of focus for
Thermo Fisher Scientific is taking bold steps toward revolutionizing drug development through its innovative Accelerator Drug Development program. This strategy aims to streamline the complex process from preclinical stages to commercialization by integrating its contract research organization
Antibody development is integral to pushing the boundaries of research, diagnostics, and therapeutics. Characterized by their high specificity and affinity, antibodies are critical for detecting and neutralizing biological targets, leading to significant breakthroughs across various scientific
